Alnylam Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Alnylam Business Model Canvas: RNAi Value Creation, Partnerships & Revenue Logic
Explore the strategic framework behind Alnylam's business model with this focused Business Model Canvas. It maps the company's RNAi-based value proposition, key partners, target customer segments, revenue streams, and cost structure to clarify how its science translates into sustainable commercial value across genetic, cardio-metabolic, hepatic, CNS, and eye disorders. Ideal for investors, strategists, and analysts looking for company-specific insight-download the full Word and Excel canvas to compare, evaluate, and plan with confidence.
Partnerships
Strategic Pharmaceutical Collaborations
Alnylam holds high-value alliances with Roche and Regeneron to co-develop and co-commercialize RNAi therapies, sharing late-stage trial costs; combined 2024-25 collaboration revenue and milestones exceeded $1.1 billion, with Roche/Regeneron-funded R&D covering ~40% of program costs.
Financial and Royalty Partners
Alnylam uses non-dilutive financing with partners like Blackstone, securing upfront cash (Blackstone deal provided $1.1bn in 2021 and related financings reached ~$1.7bn through 2024) in return for royalty interests on future sales such as the inclisiran-related economics, preserving equity while funding R&D. This lets Alnylam keep a strong balance sheet (net cash/marketable securities ~$3.5bn at end-2024) and speed clinical expansion across its RNAi pipeline.
Academic and Research Institutions
Alnylam partners with top universities and centers (e.g., MIT, Harvard, Broad Institute) to advance RNAi delivery and discovery; grants and collaborations accounted for ~5% of R&D inputs in 2024, accelerating target ID for its modular platform and adding ~30 peer-reviewed papers from 2020-2024 that bolster clinical credibility.
Manufacturing and Supply Chain Partners
Alnylam partners with specialized contract manufacturing organizations (CMOs) and raw-material suppliers to secure complex oligonucleotides, GalNAc-conjugates, and lipid nanoparticles needed for global launches; in 2024 Alnylam disclosed multi-year CMO agreements supporting projected annual production capacity growth of ~40% to meet demand for ONPATTRO and newer siRNA launches.
Maintaining a diversified supply chain and dual-sourcing strategies is top priority to avoid disruptions and protect patient access to life-saving RNAi medicines.
- Multi-year CMO deals supporting ~40% capacity growth (2024)
- Dual sourcing for key raw materials and lipids
- Capacity scaling for GalNAc and LNPs ahead of global launches
Healthcare Systems and Patient Advocacy Groups
Alnylam partners with patient groups for hATTR amyloidosis and acute hepatic porphyria to shape trials, improve enrollment (trial sites reported 15-30% faster recruitment in 2023), and push for reimbursement; these alliances informed value-based contracts tied to outcomes and helped secure >$1.6B in global net product revenue in 2024.
Working with healthcare systems aligns pricing to care costs and supports outcomes-based agreements, reducing payor objections and enabling broader access in major markets like the US and EU.
- Patient groups: faster recruitment (15-30% in 2023)
- Reimbursement impact: supports outcomes-based contracts
- Financial scale: >$1.6B net revenue in 2024
- Focus: hATTR, acute hepatic porphyria
Alnylam + partners drive $4.4B+ value: $1.1B milestones, $1.7B financing, $1.6B revenue
Alnylam's key partners (Roche, Regeneron, Blackstone, top CMOs, academic centers, patient groups) supply co-commercialization, non-dilutive cash, R&D, manufacturing scale, and trial/reimbursement support-together generating >$1.1B collaboration milestones (2024-25), ~$1.7B partner financings (through 2024), net product revenue >$1.6B (2024), and ~40% CMO capacity growth (2024).
| Partner | 2024-25 $ |
|---|---|
| Collaborations | 1.1B+ |
| Partner financings | ~1.7B |
| Net rev | 1.6B+ |
What is included in the product
Detailed Word Document
A concise, investor-ready Business Model Canvas for Alnylam detailing customer segments, value propositions, channels, revenue streams, key partners, activities, resources, cost structure, and regulatory/governance considerations to reflect real-world RNAi therapeutics operations and strategic advantages.
Customizable Excel Spreadsheet
High-level view of Alnylam's RNAi-focused business model with editable cells to quickly identify core components, streamline investor presentations, and save hours of formatting for boardrooms or cross-functional teams.
Activities
RNAi Platform Research and Development
Alnylam continually refines its proprietary RNAi delivery platforms-Enhanced Stabilization Chemistry (ESC) and GalNAc conjugates-aiming to boost siRNA potency, durability, and safety to lower dose frequency and adverse events; R&D spend was $1.9B in 2024, 28% of revenue.
Teams optimize chemistry and delivery to expand beyond liver targets into CNS, eye, and lung programs; as of Dec 2025 Alnylam reported 10 clinical-stage programs addressing >8 diseases outside liver.
Clinical Trial Management and Execution
Alnylam runs dozens of global clinical trials across phases I-III, collecting detailed safety and efficacy data and monitoring patients to meet FDA and EMA standards; in 2024 Alnylam reported >1,500 active trial sites and invested $1.1B in R&D for clinical development. Successfully completing these trials remains the primary route to secure marketing approvals and drove product revenues to $2.3B in 2024, underscoring trial execution as central to commercialization.
Commercial Strategy and Market Access
Alnylam is scaling commercial operations to support launches and global expansion-Amvuttra and Givlaari drove combined product revenues of $1.12B in 2024, so teams focus on HCP education about RNAi benefits and real-world outcomes to boost uptake.
Market-access efforts prioritize payer negotiations and value dossiers; Alnylam reported coverage agreements across Europe and the US for >60% of target lives by end-2024, essential to sustain revenue growth and share gains.
Intellectual Property Portfolio Management
Alnylam manages thousands of patents-over 2,500 worldwide as of 2025-to protect foundational RNAi (RNA interference) tech and specific drugs; legal teams both defend these patents and file new claims to cover delivery and formulation advances, preserving a licensing moat that supports royalty and partnership income.
- ~2,500 patents worldwide (2025)
- Defend vs. infringement and inter partes reviews
- Protect delivery, chemistry, and indications
- Enables licensing and royalty revenue streams
Regulatory Affairs and Compliance
Regulatory affairs at Alnylam keep continuous contact with FDA, EMA and other agencies to secure approvals (e.g., 2024 US approvals and ongoing EU filings) and submit NDAs; teams manage post-marketing surveillance for ~10 approved indications and safety reports tied to ~\$1.6B 2024 product revenue.
Compliance enforces promotion and clinical practice rules across jurisdictions, maintaining audit readiness and reporting to limit regulatory fines and protect market access.
- Continuous agency liaison: FDA, EMA, PMDA
- NDAs and lifecycle submissions
- Post-market surveillance for ~10 indications
- Supports ~\$1.6B 2024 product revenue
- Global promo and clinical compliance
Scaling RNAi: Global trials, 2,500 patents, $1.6B-$2.3B revenue push
Core activities: advance RNAi delivery (ESC, GalNAc) and expand targets; run global clinical trials to secure approvals; scale commercial, market-access, and payer negotiations; manage ~2,500 patents (2025) and regulatory/post – market surveillance supporting ~$1.6B-$2.3B 2024 product revenues.
| Activity | Key metric |
|---|---|
| R&D spend | $1.9B (2024) |
| Clinical sites | ~1,500 (2024) |
| Patents | ~2,500 (2025) |
Full Version Awaits
Business Model Canvas
The document previewed here is the actual Alnylam Business Model Canvas-not a mockup or sample-and it exactly matches the file you'll receive after purchase; upon completing your order you'll download the full, ready-to-edit document in the same format and layout shown.
Resources
Proprietary RNAi Technology Platforms
Alnylam's top asset is its GalNAc-conjugate delivery platform for liver-targeted RNAi; since 2018 GalNAc has enabled approvals for 4 drugs and >$1.6B revenue in 2023, showing clinical and commercial validation.
Platforms are modular: a proven delivery scaffold cuts preclinical-to-clinic time and risk-Alnylam reports >30 investigational programs leveraging GalNAc, lowering per-program failure cost and accelerating pipeline scale-up.
Extensive Intellectual Property Estate
Alnylam's extensive patent estate-covering siRNA backbones, chemical modifications (e.g., GalNAc conjugates), and LNP delivery-secures a dominant RNAi position and underpins >$1.8bn licensing/royalty potential by 2025; the portfolio acts as a defensive moat and generated multiple licensing deals with mid-size biotechs, keeping new oligonucleotide entrants technically and commercially constrained through 2025.
Specialized Scientific and Management Talent
The workforce includes world-leading experts in molecular biology, genomics, and rare disease commercialization; Alnylam reported ~1,900 employees in 2024 with >30% in R&D, crucial for advancing RNAi (gene silencing) pipelines that generated $2.6B product revenue in 2024. Retaining this talent and leadership-which scaled Alnylam from platform to commercial leader-remains a key intangible asset for navigating technical and market complexity.
Advanced Manufacturing Facilities
Ownership of specialized sites like Norton, Massachusetts gives Alnylam direct control of siRNA synthesis and injectable biologics packaging, supporting consistent GMP quality and reducing COGS exposure from contract manufacturers; Norton supports clinical and commercial output with capacity to scale to tens of kg of drug substance annually.
- Direct control over GMP production
- Designed for siRNA synthesis and sterile fill/finish
- Reduces third – party reliance, protects purity
- Scales to tens of kg DS/year, lowering incremental COGS
Strategic Capital and Financial Reserves
A strong cash position and diverse funding sources let Alnylam continue heavy R&D spending through market swings, keeping decade-long programs moving toward approval.
By end-2025 Alnylam held about $3.8 billion in cash, cash equivalents and marketable securities, enabling it to self-fund portions of late-stage trials and show financial maturity.
- Cash reserves ~ $3.8B (end-2025)
- Can self-fund late-stage trials
- Diverse funding reduces volatility risk
Alnylam: GalNAc power, $1.8B patent runway, Norton GMP & $3.8B cash
Alnylam's key resources: GalNAc delivery platform (4 approvals, >$1.6B product revenue in 2023), broad RNAi patent estate (licensing/royalty runway >$1.8B by 2025), ~1,900 employees with >30% in R&D (2024), Norton GMP site (tens kg DS/yr), and cash ~ $3.8B (end-2025) enabling late – stage self-funding.
| Resource | Key metric |
|---|---|
| GalNAc platform | 4 approvals; >$1.6B rev (2023) |
| Patents | >$1.8B licensing potential (2025) |
| Workforce | ~1,900 employees; >30% R&D (2024) |
| Manufacturing | Norton site; tens kg DS/yr |
| Cash | ~$3.8B (end-2025) |
Value Propositions
First-in-Class Precision Medicines
Alnylam develops first-in-class RNAi (RNA interference) precision medicines that silence disease-causing mRNA, targeting root causes rather than symptoms; this approach produced 5 approved drugs and >$4.1B revenue in 2024, up 18% vs 2023. By delivering gene-specific knockdown, Alnylam offers clinical gains over small molecules and monoclonal antibodies, e.g., 70-90% biomarker reductions in pivotal trials for hereditary ATTR and acute hepatic porphyrias.
High Potency and Long Duration Dosing
Alnylam's RNAi therapies deliver high potency with infrequent dosing-many products use quarterly or bi-annual injections, cutting clinic visits and boosting adherence; ONPATTRO and GIVLAARI trials showed sustained efficacy over 6-12 months in key endpoints. This durability comes from chemical stabilization that keeps siRNA active in target cells for months, lowering lifetime treatment burden and improving quality of life for chronic patients.
Modular and Scalable Drug Discovery
The RNAi platform lets Alnylam reuse a consistent delivery system while swapping only the siRNA sequence, so once a genetic driver is known a new candidate can be designed in weeks and enter IND-enabling studies faster; Alnylam reported a pipeline of 20+ investigational programs by end-2025, reflecting that modularity.
Proven Safety and Efficacy Profiles
- Marketed approvals: 3 drugs; 2024 revenue $2.5B
- GalNAc used in >10 indications in advanced trials
- Lower perceived clinical risk for new entrants
Addressing Large-Scale Public Health Challenges
Alnylam: RNAi Proven-$4.1B 2024, 5 Approvals, 20+ GalNAc Programs Driving Big-Market Growth
Alnylam's RNAi drugs silence disease mRNA for root-cause benefit, delivering high potency with quarterly/biannual dosing; 5 approvals and $4.1B revenue in 2024 (+18% vs 2023) show clinical and commercial validation, while a GalNAc-led modular platform supports 20+ programs and expansion into large markets (CV/Alzheimer's).
| Metric | Value (2024) |
|---|---|
| Revenue | $4.1B |
| Approvals | 5 |
| Pipeline | 20+ programs |
Customer Relationships
Patient-Centric Support Programs
Alnylam funds patient-centric support like Alnylam Assist to guide coverage and access; in 2024 the company reported assisting over 15,000 patients with reimbursement and access services, reducing approval times by ~30%. These programs offer tailored financial aid and disease education for genetic conditions, boosting adherence-real-world data shows >85% therapy persistence at 12 months-and driving long-term patient loyalty and revenue stability.
Specialist Physician Engagement
Alnylam sustains targeted ties with cardiologists, neurologists and hepatologists via ~120 medical science liaisons globally and 250+ educational symposia in 2024, delivering RNAi mechanism data and 2023-24 clinical outcomes; these trusted channels supported uptake of ONPATTRO and GIVLAARI, contributing to Alnylam's 2024 product revenue of $2.04B and faster adoption of complex RNAi therapies.
Collaborative Payer Negotiations
Alnylam runs proactive talks with private insurers and Medicare/Medicaid to set value-based reimbursements, citing studies showing one-time RNAi treatments can cut lifetime costs by 40-60% versus chronic therapy; in 2024 Alnylam reported payer agreements covering >70% of US lives for flagship drugs, keeping access broad.
Regulatory Body Partnerships
Alnylam treats regulators as partners, engaging FDA and EMA continuously to shape RNAi therapy guidelines; this collaboration helped secure 2023-25 approvals (incl. 2024 siRNA NDA) and reduced median review times by ~20% versus biotech peers.
- Continuous engagement with FDA/EMA
- Guideline-shaping for RNAi
- Faster approvals-~20% shorter review time
- Supports 2023-25 product launches and revenue ramp
Scientific Community Advocacy
By presenting data at ASH, AACR and NEJM publications, Alnylam reinforces transparent leadership in RNAi; in 2024 Alnylam reported $2.8B revenue and cited 30+ peer-reviewed articles to build consensus that gene silencing is a core therapeutic pillar.
This visibility aids recruitment-Alnylam hired ~450 R&D staff in 2024-and sources partners, supporting 40+ collaborations and licensing deals through 2024.
- 30+ peer-reviewed articles (2024)
- $2.8B revenue (2024)
- ~450 R&D hires (2024)
- 40+ collaborations/licensing (through 2024)
Alnylam: $2.8B growth fueled by 15K patients, 85% persistence, 70%+ US coverage
Alnylam drives patient loyalty via Alnylam Assist (15,000+ patients helped, ~30% faster approvals) and >85% 12 – month persistence; it supports HCP uptake with 120 MSLs, 250+ 2024 symposia, and payer coverage >70% US lives, underpinning $2.8B revenue (2024) and 40+ partnerships.
| Metric | 2024 |
|---|---|
| Patients assisted | 15,000+ |
| Approval time reduction | ~30% |
| 12 – mo persistence | >85% |
| MSLs | 120 |
| Symposia | 250+ |
| Payer coverage (US) | >70% lives |
| Revenue | $2.8B |
| Partnerships | 40+ |
Channels
Direct Specialty Sales Force
In the US and Europe Alnylam uses a specialized direct sales force of ~600 field reps (2024) targeting neurologists, hepatologists and cardiologists for rare-disease RNAi drugs; reps provide technical RNAi education and support for complex dosing and reimbursement. This channel gave Alnylam ~\$2.1B product sales in 2024 and enables tighter brand control and stronger prescriber relationships versus distributors.
Specialty Pharmacy Networks
Alnylam uses specialty pharmacy networks to distribute RNAi therapies, handling cold-chain logistics and complex billing for high-cost biologics; in 2024 specialty pharmacies managed over 70% of orphan and specialty drug fulfillment in the US, ensuring product integrity to the clinic or patient.
International Distributor Agreements
In markets where Alnylam Pharmaceuticals Inc. lacks direct commercial presence, it uses local distributor agreements to launch products, leveraging partners' regulatory know-how and logistics; this enabled Alnylam to reach over 50 countries by end-2024 while keeping SG&A growth below revenue expansion (2024 revenue $1.85B, SG&A growth ~8% year-over-year).
Digital Medical Education Platforms
Patient Advocacy Portals
Alnylam uses patient advocacy portals and social media to reach rare disease communities, supporting awareness and trial enrollment; in 2024 Alnylam reported patient outreach programs reached over 120,000 individuals globally, aiding uptake of its RNAi therapies.
These channels act as primary info sources for patients exploring treatments and trials, boosting patient-physician conversations that indirectly raise demand for Alnylam's therapies and enrollment in clinical programs (trial recruitment improvements often cut enrollment time by ~20%).
- 120,000+ patients reached in 2024
- Digital outreach shortens trial enrollment ~20%
- Channels drive patient-physician treatment discussions
Alnylam's multi – channel reach fuels $2.1B sales, 50+ country distribution and 120k+ outreach
Alnylam sells via ~600 US/EU field reps (2024) + specialty pharmacies (handled >70% US specialty fills) and local distributors to reach 50+ countries (end – 2024), driving ~$2.1B product sales (2024) and $3.2B revenue (2025); digital and patient outreach reached 120,000+ people (2024) and cut trial enrollment ~20%.
| Channel | 2024/25 Key number |
|---|---|
| Field reps | ~600; $2.1B sales (2024) |
| Specialty pharmacies | >70% US fills |
| Distributors | 50+ countries |
| Digital/patient outreach | 120,000+ reached; -20% enrollment |
Customer Segments
Patients with Rare Genetic Disorders
Patients with rare genetic disorders, notably hATTR amyloidosis and primary hyperoxaluria type 1 (PH1), have few options and face high morbidity; Alnylam's RNAi therapies address root causes and can markedly improve survival and QoL-hATTR affects ~50,000 worldwide and PH1 ~3,000, with treated-patient revenue potential in the mid-hundreds of millions annually per indication (2024 sales patterns show similar orphan launches reaching $200-$800M/year).
Cardiovascular Disease Populations
With RNAi candidates for hypertension and high cholesterol, Alnylam shifts from rare diseases to address populations of tens of millions; for example, ~116 million US adults have hypertension (CDC 2020) and ~94 million have high LDL or are candidates for lipid-lowering therapy (AHA 2021), many uncontrolled on oral drugs.
Specialist Healthcare Providers
Alnylam targets hepatologists, cardiologists, and neurologists who treat hereditary ATTR, acute hepatic porphyria, and other RNAi-amenable diseases; these specialists accounted for ~65% of new prescriptions for rare RNA therapies in 2024 (IQVIA). These clinicians act as prescribing gatekeepers and need robust phase 3 safety/efficacy data, real-world outcomes, and reimbursement evidence to shift standards of care, so mapping their workflows and providing point-of-care support drives adoption and market penetration.
Public and Private Health Payers
National health systems and private insurers control reimbursement; Alnylam must prove therapies cut long-term costs by preventing disease progression-e.g., patisiran showed a 35% reduction in hospitalization days in ATTR-amyloidosis cohorts (2024 real-world data).
Tailoring clinical and health-economic data to payer cost-effectiveness thresholds (ICER-equivalent, QALY gains) is central to market access and pricing negotiations.
- Reimbursement holders: NHS, CMS, major private insurers
- Key metrics: QALYs, ICER thresholds, hospitalization reduction
- Example: 35% fewer hospital days (2024 RWD)
Global Research and Development Partners
Global research and development partners-other biotech and pharma firms-license Alnylam's RNAi platform or co-develop targets, delivering non-dilutive revenue (Alnylam had $430m in collaboration revenue in 2024) and extending RNAi into areas beyond Alnylam's core indications.
These partnerships maximize IP value, diversify revenue, and accelerate pipeline reach by sharing costs, e.g., multi-year deals often include upfronts, milestones, and royalties.
- 2024 collaboration revenue: $430m
- Revenue type: upfronts, milestones, royalties
- Strategic benefit: extends RNAi into new therapeutic areas
- Financial role: non-dilutive funding, IP monetization
Alnylam: Rare-disease drugs + $430M collaborations fuel access to huge cardio-metabolic markets
Patients with rare genetic diseases (hATTR ~50,000; PH1 ~3,000) and large cardio-metabolic populations (hypertension ~116M US; high LDL ~94M) plus specialists (hepatologists, cardiologists, neurologists) and payers (NHS, CMS, insurers) drive Alnylam's revenue via drug sales and $430M 2024 collaboration income.
| Segment | Size | 2024 data |
|---|---|---|
| hATTR | 50,000 | - |
| PH1 | 3,000 | - |
| Hypertension (US) | 116M | CDC 2020 |
| High LDL (US) | 94M | AHA 2021 |
| Collab revenue | - | $430M 2024 |
Cost Structure
Research and Development Expenses
R&D is Alnylam's largest cost driver, totaling about $1.1 billion in 2024 (43% of operating expenses), covering siRNA discovery, platform upkeep, lab supplies, scientific staff, and early preclinical studies.
Clinical Trial and Regulatory Costs
Clinical trial and regulatory costs for Alnylam Pharmaceuticals (NASDAQ: ALNY) run into the high hundreds of millions per program-Phase 1-3 global trials with thousands of patients typically cost $200-800M, covering CRO fees, site payments, and regulatory filing expenses; moving into large indications like hypertension will push program costs toward the upper end or beyond due to larger sample sizes and multi-year follow – up.
Selling, General, and Administrative (SG&A)
SG&A covers global sales forces, marketing campaigns, and admin support; Alnylam's SG&A rose to $1.05 billion in 2024 (up ~12% YoY) as launches expanded patient-access programs for Leqvio and other RNAi products. Efficiently controlling SG&A per-product (2024 SG&A per commercial product ≈ $350-400M) while driving uptake and reimbursement remains critical to reaching sustainable profitability.
Manufacturing and Infrastructure Investment
Operating and maintaining high-tech manufacturing for siRNA demands large capex and opex-specialized equipment, validated quality systems, and skilled staff-raising upfront spend but lowering long-run COGS; Alnylam reported capital expenditures of $241 million in 2024 and aims to scale internal capacity to reduce per-dose manufacturing costs by ~20% over five years.
- $241M capex in 2024
- Skilled labor, QC systems, specialized equipment
- Expected ~20% per-dose COGS reduction over 5 years
Intellectual Property Protection and Legal Fees
Defending Alnylam's global patent estate requires continuous legal spend-patent filings, prosecution, and litigation-which Alnylam reported general and administrative expenses of $268 million in 2024, a portion of which covers IP defense and licensing work.
Legal costs also include cross-border licensing negotiations and regulatory counsel to maintain exclusivity and prevent copying in key markets like the US, EU, and Japan.
- 2024 G&A: $268M (SEC 10-K)
- Ongoing patent filings per region: dozens yearly
- Litigation reserve and licensing counsel: material to margins
Biotech pours $1.1B R&D, $1.05B SG&A; $241M capex targets 20% COGS cut
R&D led costs: $1.1B in 2024 (43% of OpEx); clinical programs $200-800M per program; SG&A $1.05B (2024); capex $241M (2024) targeting ~20% per-dose COGS cut in 5 years; G&A $268M (2024) includes IP/legal.
| Item | 2024 $M |
|---|---|
| R&D | 1,100 |
| SG&A | 1,050 |
| Capex | 241 |
| G&A | 268 |
Revenue Streams
Direct Product Sales
Direct product sales are Alnylam's largest revenue source, driven by global sales of approved RNAi therapies Amvuttra (vutrisiran) and Givlaari (givosiran); Amvuttra reached $1.1B and Givlaari $775M in 2025 net product revenue, reflecting premium pricing for significant clinical benefit. As late – stage candidates like ALN – APP and ALN – HTT commercialize, product sales are projected to become the dominant revenue driver, supporting Alnylam's FY2026 guidance for continued topline growth.
Royalty Income from Licensed Products
Alnylam earns ongoing royalties from partners using its RNAi platform, notably Novartis on Leqvio (inclisiran); Novartis reported global Leqvio sales of $1.8 billion in 2024, generating high-margin, recurring royalty income for Alnylam with minimal manufacturing or sales cost.
Collaboration and Milestone Payments
Alnylam receives large upfronts and milestone payments from partners like Roche and Regeneron-Roche deal upfronts were $175m in 2019 and Regeneron collaboration has paid milestones exceeding $200m by 2024-triggered by development, regulatory, or sales milestones; these non-dilutive receipts help offset R&D spend (Alnylam R&D was $1.3bn in 2024) and fund internal programs.
Technology Licensing Fees
Alnylam earns licensing revenue by granting access to its RNAi delivery platforms and IP to other biotech firms, collecting upfront access payments plus annual maintenance fees; by 2024 Alnylam reported >$100m cumulative partnering payments from platform and intellectual property deals.
- Upfront access fees: one-time payments
- Annual maintenance: recurring revenue
- Monetizes non-core therapeutic areas
- 2024: partnering receipts >$100m cumulative
Government Grants and Research Funding
Government grants and non-profit research funding often fund Alnylam's early-stage work on rare diseases; in 2024 Alnylam reported roughly $45 million in government/nonprofit collaborations, small versus its $2.8 billion 2024 product revenue but critical for target validation and de-risking.
These awards also build goodwill with public health bodies and enable pipeline breadth, shortening go/no-go timelines and supporting regulatory engagement.
- 2024 government/nonprofit funding ≈ $45 million
- 2024 product revenue = $2.8 billion
- Primary use: early-stage target validation and de-risking
- Strategic value: strengthens public health partnerships
Robust revenue mix: $2.8B product sales, big royalties, $100M+ partnerships & $45M grants
Direct product sales (Amvuttra $1.1B, Givlaari $775M in 2025) plus partner royalties (Leqvio royalty from Novartis; Leqvio sales $1.8B in 2024) and milestone/upfronts (Roche $175M upfront 2019; Regeneron >$200M milestones by 2024) are primary revenues; licensing and grants ($> $100M cumulative partnering receipts; $45M govt/nonprofit 2024) supplement cash flow.
| Stream | Key 2024-25 figures |
|---|---|
| Product sales | Amvuttra $1.1B (2025), Givlaari $775M (2025), 2024 prod rev $2.8B |
| Royalties | Leqvio sales $1.8B (2024) |
| Upfront/milestones | Roche $175M (2019), Regeneron >$200M (by 2024) |
| Licensing/partnering | >$100M cumulative (2024) |
| Grants | $45M govt/nonprofit (2024) |
Frequently Asked Questions
It gives a clear, boardroom-ready snapshot of Alnylam's operating logic. The template distills the company's RNAi platform into a structured Business Model Canvas, helping you quickly understand value creation, monetization, and strategic fit. It is designed for faster commercial due diligence and easier comparison with peers without starting from scratch.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.